Published: 2019 June 13
Updated : 2023 January 16

Blood Culture Tests Market

SKU : CD1183
180 pages
Report Summary
Table of Contents
List of Tables & Figures

Blood Culture Tests Market Overview 2023-2030

Blood Culture Tests Market was valued at USD 4357.91 million in 2022 and is estimated to reach USD 8600.93 million by 2030, growing at a CAGR of 9.1% during the forecast period 2023-2030. Blood culture tests are procedures to detect an infection in the blood and identify the cause. Infections of the bloodstream are most caused by microorganisms such as bacteria, fungi, and yeast. Growing prevalence of blood-related infections, high mortality, and morbidity from sepsis, the need for advanced diagnostic techniques drives the global blood culture tests market over the forecast period.

Blood Culture Tests Market - Strategic Insights



Market CAGR


Segments Covered

By Product, By Technology, By Application, By End-User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To Get a Free Sample Click here

Market Dynamics

Various factors are responsible for the market's growth, such as an increase in the prevalence of infectious blood infections across the globe and awareness among the population regarding infectious diseases. An increase in novel technological advancements and product launches contributes to the growth of the blood culture test market.

The increasing number of novel product launches and the rising demand for blood culture tests will drive market growth.     

The global market for blood culture tests is primarily driven by the surge in demand for these diagnostics; the rising number of novel product launches. An increase in infectious blood disease cases is also aiding the market growth. There has been an increase in R&D activities by many healthcare companies to develop advanced products such as instruments, consumables, and software.

Investment in R&D for developing the new product is a crucial strategy of vendors to support the long-term growth of their businesses, and the latest innovative launches are driving the market growth. For instance, in May 2020, Luminex Corporation launched VERIGENE BC-GN, an in-vitro, multiplexed qualitative diagnostic test that detects species, genus and genetic resistance markers for gram-negative bacteria from bottles of positive blood culture.

Various funding, novel technological advancements, and the number of the latest product launches are increasing, leading to the high demand for blood culture tests. For instance, in Jul 2022, T2 Biosystems announced that its T2Lyme Panel, a molecular diagnostic test direct from the blood, received a breakthrough device designation by the U.S.FDA. This runs on a T2Dx instrument that will detect the Lyme disease-causing bacteria from the patient’s blood to support early diagnosis.

The stringent regulations associated with diagnostic products will hamper the market’s growth.  

However, stringent government regulations for developing and manufacturing diagnostic products, including blood culture test products, could hinder the market growth. Products undergo multiple trials for approval which increases the cost of development.

COVID-19 Impact Analysis

The pandemic has positively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The blood culture tests market has experienced huge growth and profit due to COVID, as all the research and clinical trials started in full swing due to COVID. And now, various initiatives, collaborations and mergers are happening worldwide, boosting the market’s growth. For instance, in Apr 2020, Thermo Fisher created several PCR kits and tests for diagnostic and research to fight the COVID-19 outbreak. They released AcroMetrix Coronavirus 2019 (COVID-19) RNA Control after receiving the US FDA's emergency use authorization (EUA) for the SARS CoV 2 multiplex real-time PCR test.

Segment Analysis

The consumables segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

By Product:

  • Consumables
  • Blood Culture Media
  • Assay
  • Kits and Reagents
  • Blood Culture Accessories
  • Others

By Technology:

  • Culture-based Technology
  • Molecular Technology
  • Proteomic Technology

By Application:

  • Bacterial Infections
  • Fungal Infections
  • Mycobacterial Infections

The consumables segment is the highest market holder in the global blood culture tests market. Consumables growth is attributed to the increased adoption of blood culture tests for diagnostic purposes, including blood culture media, assays, kits and reagents, and blood culture accessories, primarily because it involves high precision and low cost. The blood culture media is generally used to identify bacterial or fungal infections present in the blood and to distinguish the type of infection for treatment purposes. These tests detect blood infections that can lead to critical and life-threatening complications like sepsis. The growth trend will continue in the coming years, with new products being developed and introduced into the market. Companies are focusing on developing devices and solutions that are accurate, have low cost and show high efficacy.

The consumables segment dominates the market due to the rising awareness of infectious blood diseases. The growing number of regulatory approvals, technological advancements, product launches, and research studies drive the market’s growth. For instance, in Jan 2021, Bruker Corporation announced the clearance of MBT Sersityper Kit US IVD, a microbial raid identification of around 425 microbes on MALDI BiotyperCASystem from the positive blood cultures by the U.S. Food and Drugs Administration.

Geographical Analysis

North America holds the largest market share of the global blood culture tests market.

North America dominates the global blood culture tests market, primarily attributed to the increasing development in healthcare facilities and increased investment by government and non-government organizations to develop new diagnostics tests. The increased adoption of the latest technologies for blood culture testing and the increasing prevalence of infectious blood diseases are leading to the demand for diagnostic test products. According to BD (Becton Dickinson), an estimated 31.5 million sepsis cases are diagnosed each year globally, with an estimated 5.3 million deaths. The presence of key players in the region contributes to the growth of the blood culture test market.

Moreover, the growing number of product launches is responsible for the market’s growth. Other factors, such as the high spending on these products, stimulate the market’s growth. Many key developments, technological advancements, collaborations and agreements are taking place in this region. For instance, in Mar 2022, Thermo Fisher Scientific announced the launch of two novel reverse transcriptions loop-mediated isothermal amplification-based (RT-LAMP) solutions for the surveillance of infectious pathogens and supported active research. PCR is unmatched for lab-based testing and diagnostics; this isothermal RT-LAMP provides a low-cost option for detecting infections.

Competitive Landscape

The blood culture test market is highly competitive with local and global companies’ presence. Thermo Fisher Scientific Inc., Becton Dickinson and Company, Abbott Laboratories, bioMerieux S.A., Danaher Corporation, F. Hoffman-La Roche, Luminex Corporation, Bruker Corporation, OpGen Inc., T2 Biosystems Inc. and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in Se 2022, OpGen Inc., a company in precision medicine, announced its collaboration agreement for R&D with FIND for applying molecular diagnostics and bioinformatics for combating infectious diseases. This alliance will provide the Unyvero A30 RQ platform that can be utilized in rapid pathogen ID and AMR testing from samples of blood culture.

Thermo Fisher Scientific Inc:


Thermo Fisher Scientific is a healthcare distributor company that serves science. They manufacture and market reagents, scientific instruments & equipment, consumables and software services. It was established in 1956 and is based in Waltham, Massachusetts, United States.

­Product Portfolio:

VersaTREK REDOX EZ Draw Media: It is a culture media that is simple, convenient, and safe to perform phlebotomy that does not require expensive blood adapters. Its FDA cleared that accommodate around 5mL of blood. EZ draw media can be used for automatic or manual monitoring of blood samples generally accessible in 40mL broth for aerobic REDOX-1 and anaerobic REDOX-2. REDOX media is highly-enriched and supports a variety of organisms that enhance the VersaTREK system.

Key Development: In Sep 2022, Thermo Fisher certified their Applied Biosystems QuantStudio 7 Pro Dx, a real-time PCR, as it fulfills all the requirements by novel in-vitro medical devices regulation. Now it includes the biosystem Diomni Software ecosystem to grant labs and developers tests to support flexible PCR testing.

The global blood culture tests market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.  

Trending Topics

Renal Biomarkers Market

Cosmetic Surgery Market

Telemedicine Market

Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy